Prevalence of Long COVID-19 in the Canary Islands

Launched by UNIVERSITY OF LAS PALMAS DE GRAN CANARIA · Feb 5, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the prevalence of Long COVID-19 in the Canary Islands. Long COVID refers to a condition where people who have recovered from COVID-19 continue to experience symptoms for weeks or months after their initial infection. The goal of this study is to understand which patients are at higher risk for developing Long COVID and to help plan for their ongoing care. Researchers want to learn more about the common signs and symptoms experienced by these patients at least 12 weeks after their COVID-19 diagnosis.

To participate in the trial, individuals must have tested positive for COVID-19 since March 14, 2020, and should have ongoing symptoms related to the virus at least 12 weeks after their diagnosis. Participants need to be able to understand and complete the evaluation tests. However, those with certain pre-existing conditions, like fibromyalgia or chronic fatigue syndrome, will not be eligible. If you join the study, you can expect to undergo assessments that will help researchers gather important information about Long COVID and its effects on daily life. This research is crucial for better understanding and addressing the challenges faced by those affected by Long COVID.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Have been positive for COVID-19 since the declaration of the state of alarm throughout the Spanish territory to deal with the health emergency situation caused by COVID-19 (March 14, 2020).
• • Symptoms associated with COVID-19 at least after 12 weeks of its detection.
• • Adequate cognitive and physical level to understand and perform the tests evaluation.
• Exclusion Criteria:
• • Present comorbidities prior to suffering from COVID-19 whose symptoms are resemble Post-acute COVID-19.
• • Fibromyalgia.
• • Chronic fatigue.
• • Neuromuscular disease.
• • Not having signed the informed consent.
• • Person undergoing treatment for active cancer.